SHMT2 controls Burkitt lymphoma cell survival by maintaining an oncogenic TCF3 transcriptional program

ABSTRACT: In this study, the human Burkitt’s Lymphoma cell line BL60 has been analysed via proteomic and phosphoproteomic analysis for effect of a knock down of the serine hydroxymethyltransferase 2 (shSHMT2) compared to a control construct (shGL2). Concerning the phosphoproteome, these results have been compared to an analysis of a knock down of CD79a (shCD79a) in these cells.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Burkitt Lymphoma Cell Line

DISEASE(S): Burkitt Lymphoma

SUBMITTER: Anne Wilke  

LAB HEAD: Thomas Oellerich

PROVIDER: PXD018961 | Pride | 2023-03-10

REPOSITORIES: Pride